Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
about
Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy.Novel vaccination approaches to prevent tuberculosis in childrenbioA mutant of Mycobacterium tuberculosis shows severe growth defect and imparts protection against tuberculosis in guinea pigs.Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In VivoMTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice.Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6.Mycobacterium tuberculosis sigE mutant ST28 used as a vaccine induces protective immunity in the guinea pig model.Towards new TB vaccines: What are the challenges?Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines.Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis.The Enigmatic PE/PPE Multigene Family of Mycobacteria and Tuberculosis Vaccination.MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.The BCG Strain Pool: Diversity Matters.Translational Research in the Nonhuman Primate Model of Tuberculosis.Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis.Non-pathological infection of macaques by an attenuated mycobacterial vaccine is not reactivated in the setting of HIV coinfection.Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trialsTBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical DevelopmentPolyfunctional CD4+ T Cells As Targets for Tuberculosis VaccinationTuberculosis vaccines: Opportunities and challenges.MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic.An attenuated quadruple gene mutant of Mycobacterium tuberculosis imparts protection against tuberculosis in guinea pigs.CD1b Tetramers Identify T Cells that Recognize Natural and Synthetic Diacylated Sulfoglycolipids from Mycobacterium tuberculosis.Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines.The current status, challenges, and future developments of new tuberculosis vaccines.Comparative 'omics analyses differentiate Mycobacterium tuberculosis and Mycobacterium bovis and reveal distinct macrophage responses to infection with the human and bovine tubercle bacilli.Gene expression models based on a reference laboratory strain are poor predictors of Mycobacterium tuberculosis complex transcriptional diversity.Progress and challenges in TB vaccine development.Vaccines for Leprosy and Tuberculosis: Opportunities for Shared Research, Development, and Application.Validation of a CD1b tetramer assay for studies of human mycobacterial infection or vaccination.
P2860
Q33762986-94A5FFDA-6822-4BBB-8163-CAE0A325781FQ33801426-1028E063-7891-4FF8-B018-28DC69C92174Q33848397-F6579C51-35FB-438D-844C-8C47C8191999Q35982800-DB725DFB-9508-48DC-B23D-CE16F27754F5Q36504099-C68F6DFC-C40A-452B-80CE-B68FD3420264Q37741088-5209AD9C-12C2-49E3-AC51-21702F33DC37Q38627716-961C8F0C-7B66-45DC-A673-D782E0B91F2DQ38767468-D63BDDDB-12AE-4E9F-8FEE-8816ECEB910AQ38849791-70109831-1097-42CE-9AA9-1323E1B88519Q38886409-0B744A11-1B52-40A1-A3F0-9CBB7DDC6D0FQ39203406-F902CAB8-C7ED-4CD9-950F-C30319BF545FQ39266421-F85926AE-2BBF-435D-8EDB-08C5B897AA3EQ39788557-F0B7222B-CB0E-43EB-A559-4A7856C99A4EQ40175400-709E7DDE-D0F9-4259-B08E-EFDDE47BED27Q41077364-73A7A41D-C635-42FC-B199-110BF5DB2B7DQ41932554-9AB07AC4-81F8-4861-967A-B2BF20FC5740Q41987317-D0715DBD-2A6C-4C67-A270-92040CDFE6C7Q42372774-22D0A30F-DA25-4C3D-B7D5-E4D46C26FB45Q42373425-42C088D3-00CB-4E5E-ADD1-304A53298A43Q47552546-85EA897C-82DD-4506-BE92-D5C0C323B4DAQ47658864-D2AA6338-4D5C-4514-81A8-26BEF65F065EQ48115416-DBB758A6-64F6-46B6-95D4-CDACE3D93D24Q49340452-7D877BA0-733B-4F4E-B9BB-2FE95AE0F5FAQ51742073-D99934EE-08F9-42BC-AF96-DAF6E2E4A9F8Q52337140-530D828C-9F0F-4D1F-ADB8-C4B5094AD755Q52349111-D6D1809C-2A93-4A71-8159-FA90B21BD1D5Q52371356-6D9DAC15-2838-4105-852C-658A452CD7D5Q52641498-5D7AA25E-F98A-41B5-BE78-24E8D5BDDD0FQ52657152-0A03903D-438B-48A1-87DF-839E709229DDQ52717409-0908606D-4D1D-45A8-BD23-9F817DEC97E4
P2860
Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Safety of human immunisation w ...... ind, controlled phase I trial.
@en
type
label
Safety of human immunisation w ...... ind, controlled phase I trial.
@en
prefLabel
Safety of human immunisation w ...... ind, controlled phase I trial.
@en
P2093
P921
P1476
Safety of human immunisation w ...... ind, controlled phase I trial.
@en
P2093
Anne-Christine Thierry
Carole E Mayor
Catherine Lazor-Blanchet
Dessislava Marinova
Eugenia Puentes
François Spertini
Juana Doce
Laure Vallotton
Nacho Aguilo
Nils Rettby
P304
P356
10.1016/S2213-2600(15)00435-X
P577
2015-11-16T00:00:00Z